Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

2.

Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.

Fujiwara T, Urata Y, Tanaka N.

Curr Cancer Drug Targets. 2007 Mar;7(2):191-201. Review.

PMID:
17346111
3.

Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.

Fujiwara T, Urata Y, Tanaka N.

Front Biosci. 2008 Jan 1;13:1881-6. Review.

PMID:
17981675
4.

Targeting gene-virotherapy for cancer.

Liu XY, Gu JF, Shi WF.

Acta Biochim Biophys Sin (Shanghai). 2005 Sep;37(9):581-7. Review.

5.

Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.

Kyo S, Takakura M, Fujiwara T, Inoue M.

Cancer Sci. 2008 Aug;99(8):1528-38. doi: 10.1111/j.1349-7006.2008.00878.x. Review.

6.
7.

Cancer-specific gene therapy.

Lo HW, Day CP, Hung MC.

Adv Genet. 2005;54:235-55. Review.

PMID:
16096014
8.

Telomerase-dependent gene therapy.

Wirth T, Kühnel F, Kubicka S.

Curr Mol Med. 2005 Mar;5(2):243-51. Review.

PMID:
15974879
9.

Telomerase promoter-driven cancer gene therapy.

Gu J, Fang B.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S64-70. Review.

PMID:
14508082
10.

Tumor-targeting amino acid auxotrophic Salmonella typhimurium.

Hoffman RM.

Amino Acids. 2009 Sep;37(3):509-21. doi: 10.1007/s00726-009-0261-8. Review.

PMID:
19291366
11.

Improving live attenuated bacterial carriers for vaccination and therapy.

Loessner H, Endmann A, Leschner S, Bauer H, Zelmer A, zur Lage S, Westphal K, Weiss S.

Int J Med Microbiol. 2008 Jan;298(1-2):21-6. Review.

PMID:
17702649
12.

Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.

Dietrich G, Spreng S, Favre D, Viret JF, Guzman CA.

Curr Opin Mol Ther. 2003 Feb;5(1):10-9. Review.

PMID:
12669465
13.

Telomerase as a universal tumor-associated antigen for cancer immunotherapy.

Vonderheide RH.

Oncogene. 2002 Jan 21;21(4):674-9. Review.

14.

Harnessing telomerase in cancer therapeutics.

Fakhoury J, Nimmo GA, Autexier C.

Anticancer Agents Med Chem. 2007 Jul;7(4):475-83. Review.

PMID:
17630922
15.

Telomerase as a promising target for human cancer gene therapy.

Saretzki G, von Zglinicki T.

Drugs Today (Barc). 2003 Apr;39(4):265-76. Review.

PMID:
12743642
16.

CD40 ligand immunotherapy in cancer: an efficient approach.

Kuwashima N, Kageyama S, Eto Y, Urashima M.

Leuk Lymphoma. 2001 Nov-Dec;42(6):1367-77. Review.

PMID:
11911421
17.

Alphavirus vectors for cancer therapy.

Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C.

Virus Res. 2010 Nov;153(2):179-96. doi: 10.1016/j.virusres.2010.07.027. Review.

PMID:
20692305
18.

Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.

Chang SY, Kim YJ, Ko HJ.

Hum Vaccin Immunother. 2013 Aug;9(8):1654-60. doi: 10.4161/hv.24917. Review.

19.

[Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules].

Hernández-Luna MA, Luria-Pérez R, Huerta-Yépez S.

Rev Invest Clin. 2013 Jan-Feb;65(1):65-73. Review. Spanish.

PMID:
23745445
20.

Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells.

Saltzman DA.

Expert Opin Biol Ther. 2005 Apr;5(4):443-9. Review.

PMID:
15934824
Items per page

Supplemental Content

Support Center